Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-15
2011-03-15
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S285000, C544S287000, C544S290000
Reexamination Certificate
active
07906521
ABSTRACT:
The present invention relates to compounds useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.
REFERENCES:
patent: 4016166 (1977-04-01), Noda et al.
patent: 5155110 (1992-10-01), Connor et al.
patent: 5891904 (1999-04-01), Stief et al.
patent: 6037345 (2000-03-01), Pamukcu et al.
patent: 6054487 (2000-04-01), Sekut et al.
patent: 6083483 (2000-07-01), Stief et al.
patent: 6191161 (2001-02-01), Kanai et al.
patent: 2 120 663 (1971-11-01), None
patent: 2348921 (1977-11-01), None
patent: 1311573 (1973-03-01), None
patent: WO2005/117876 (2005-12-01), None
Ozaki, et al., Chemical & Pharmaceutical Bulletin, vol. 28, No. 3, Mar. 1980, pp. 702-707.
Ozaki, Kenichi et al., “Studies on 4(1H)-quinazolinones. 5. Synthesis and Antiinflammatory Activity of 4(1H)-Quinazolinone Derivatives”, Journal of Medicinal Chemistry, vol. 28(5), pp. 568-576, XP-002984298, (1985).
Noda, Kanji et al., “Quinazoline Derivatives”, Database CA Chemical Abstracts Service, Columbus, Ohio; XP-002520055, retrieved from STN Database accession No. 1977:568088, Hisamitsu Pharmaceutical Co., Inc., (1977).
Blatter, Herbert M. et al., “The Synthesis of 1,2-disubstituted 4-quinazolinones and Related Thiones”, Database CA Chemical Abstracts Service, Columbus, Ohio; XP-002520056, retrieved from STN Database accession No. 1965:82546, Organic Chemistry, vol. 30(4), pp. 1020.7, (1965).
Ozaki, Kenichi et al., “Studies on 4(1H)-quinazolinones. 2. Synthesis of 6a, 7-dihydro-5H-quinazolino[1,2-a] quinazoline-5,8(6H)-diones”, Database CA Chemical Abstracts Service, Columbus, Ohio; XP-002520057, retrieved from STN Database accession No. 1981-192256, Journal of Organic Chemistry, vol. 46(8), pp. 1571-5, (1981).
Al-Azizi, M. M. et al., “GC/MS Analysis of the Volatile Oil of the Leaves of Callistemon Specious Anthor”, Database CA Chemical Abstracts Service, Columbus, Ohio; XP-002520058, retrieved from STN Database accession No. 1996:564004, Journal of Pharmaceutical Sciences, vol. 16, pp. 10-17, (1995).
Das, B. et al., “Studies on Quinazoline-2,4-diones”, Database CA Chemical Abstracts Service, Columbus, Ohio; XP-002520059, retrieved from STN Database accession No. 1963:435623, Journal of the Indian Chemical Society, vol. 40(1), pp. 35-38, (1963).
Moore, James A. et al., “Reactions of Anthranilamide and o-aminoacetophenone with Benzil and Benzoin”, Database CA Chemical Abstracts Service, Columbus, Ohio; XP-002520060, retrieved from STN Database accession No. 1969:413087, Journal of Organic Chemistry, vol. 34(4), pp. 887-892, (1969).
Supplementary European Search Report dated Mar. 30, 2009; Application No. EP 04 78 4367.
Choi, BH et al., Direct inhibition of the cloned Kv1.5 channel by AG-1478, a tyrosine kinase inhibitor, American Journal of Physiology Cell Physiology vol. 282, Feb. 20, 2002, pp. 1461-1468.
Isaacs Richard
Trotter B. Wesley
Daniel Mark R.
Merck Sharp & Dohme Corp.
Parr Richards S.
Stuse Heidi M.
Truong Tamthom N
LandOfFree
Quinazoline potassium channel inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazoline potassium channel inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazoline potassium channel inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2657085